Algernon Pharmaceuticals is one of the few companies aiming to develop the classic psychedelic N,N-Dimethyltryptamine (DMT). Most recently, the company’s Algernon NeuroScience announced its plans to explore DMT as a treatment for traumatic brain injury (TBI). The company plans on launching a Phase 2 study in the fourth quarter of 2023 to test its potential in TBI. There are currently no drugs approved for the condition.
Preclinical studies have shown that DMT has promise for treating neurological disorders, including stroke and traumatic brain injury.
Early this year, Algernon launched a Phase 1 study of DMT in the Netherlands to find a safe and well-tolerated sub-psychedelic IV drug dose.A Phase 1 study is underway
Algernon announced that investigators had completed dosing the first participant group in the Phase 1 study. They found no safety or tolerability problems. Additionally, the safety review committee overseeing the investigation has give…